Can Oral Methotrexate Cause Neutropenia?
Yes, oral methotrexate can cause neutropenia and other forms of bone marrow suppression including pancytopenia, leukopenia, and thrombocytopenia, particularly in patients with risk factors such as advanced age, renal impairment, previous chemotherapy, or inadequate folate supplementation. 1
Mechanism and Incidence
Methotrexate suppresses hematopoiesis through its antifolate effects, leading to anemia, aplastic anemia, pancytopenia, leukopenia, neutropenia, and thrombocytopenia. 1 The FDA label explicitly warns that in patients with malignancy and preexisting hematopoietic impairment, methotrexate should be used with extreme caution or avoided entirely. 1
In controlled clinical trials for rheumatoid arthritis, leukopenia (WBC <3000/mm³) occurred in approximately 2% of patients, thrombocytopenia (platelets <100,000/mm³) in 5%, and pancytopenia in 2%. 1 However, case reports demonstrate that severe, life-threatening bone marrow suppression can occur even with low-dose methotrexate therapy, sometimes within weeks of initiation. 2
High-Risk Patient Populations
Patients with previous chemotherapy or radiation therapy are at substantially elevated risk for methotrexate-induced neutropenia. 3 The NCCN identifies previous chemotherapy or radiation as a specific risk factor for developing febrile neutropenia when exposed to myelosuppressive agents. 3, 4
Additional risk factors that increase neutropenia risk include:
- Age ≥65 years - the most important risk factor for severe neutropenia 3, 5, 4
- Renal impairment - methotrexate is renally cleared, and impaired function dramatically increases toxicity risk 1, 6
- Preexisting neutropenia or bone marrow involvement with tumor 3, 4
- Poor performance status 3, 4
- Liver dysfunction, especially elevated bilirubin 3, 4
- Folate deficiency - routine assessment is crucial in methotrexate-treated patients 7
Clinical Presentation and Timeline
Methotrexate-induced neutropenia can manifest acutely (within 2-4 weeks of initiation) or after prolonged use. 2 One documented case showed pancytopenia developing within 3 weeks of starting 15 mg weekly methotrexate, with absolute neutrophil count dropping to 220 cells/μL. 2
In patients with cancer history who have received prior chemotherapy or radiation, the risk of rapid-onset severe neutropenia is heightened due to pre-existing bone marrow compromise. 3
Monitoring Requirements
For psoriasis and rheumatoid arthritis patients, the FDA mandates that methotrexate should be stopped immediately if there is a significant drop in blood counts. 1 In elderly patients, more frequent monitoring is essential as post-marketing experience suggests bone marrow suppression and thrombocytopenia occurrence increases with age. 1
Patients with profound granulocytopenia and fever require immediate evaluation and usually need parenteral broad-spectrum antibiotic therapy. 1
Critical Pitfall to Avoid
The most dangerous pitfall is failing to recognize that "low-dose" methotrexate (7.5-25 mg weekly) can still cause life-threatening bone marrow suppression, especially in patients with renal impairment or prior chemotherapy/radiation exposure. 2, 6 Even minimal serum methotrexate levels (0.05 umol/L) have been associated with severe pancytopenia in vulnerable patients. 2
Management of Methotrexate-Induced Neutropenia
When neutropenia develops:
- Immediately discontinue methotrexate 1, 2
- Administer high-dose folic acid and leucovorin (folinic acid 20 mg daily) 2, 8
- Consider G-CSF (filgrastim) for severe neutropenia (ANC <500 cells/μL) 8
- Initiate broad-spectrum antibiotics if febrile or ANC <500 cells/μL 1
- In severe cases with renal impairment, continuous renal replacement therapy can decrease serum methotrexate concentration 6
Recovery typically occurs within 7-14 days after methotrexate discontinuation and supportive care, with complete normalization of blood counts within one month. 2